Development and Validation of a Risk Score for Post-Transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients.

Détails

Ressource 1Télécharger: 35805050_BIB_3EF953BEBC36.pdf (338.24 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_3EF953BEBC36
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Development and Validation of a Risk Score for Post-Transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients.
Périodique
Cancers
Auteur⸱e⸱s
Dos Santos Q., Wareham N.E., Mocroft A., Rasmussen A., Gustafsson F., Perch M., Sørensen S.S., Manuel O., Müller N.J., Lundgren J., Reekie J.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Statut éditorial
Publié
Date de publication
04/07/2022
Peer-reviewed
Oui
Volume
14
Numéro
13
Pages
3279
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Post-transplant lymphoproliferative disease (PTLD) is a well-recognized complication after transplant. This study aimed to develop and validate a risk score to predict PTLD among solid organ transplant (SOT) recipients. Poisson regression identified predictors of PTLD with the best fitting model selected for the risk score. The derivation cohort consisted of 2546 SOT recipients transpanted at Rigshospitalet, Copenhagen between 2004 and 2019; 57 developed PTLD. Predictors of PTLD were high-risk pre-transplant Epstein-Barr Virus (EBV), IgG donor/recipient serostatus, and current positive plasma EBV DNA, abnormal hemoglobin and C-reactive protein levels. Individuals in the high-risk group had almost 7 times higher incidence of PTLD (incidence rate ratio (IRR) 6.75; 95% CI: 4.00-11.41) compared to the low-risk group. In the validation cohort of 1611 SOT recipients from the University Hospital of Zürich, 24 developed PTLD. A similar 7 times higher risk of PTLD was observed in the high-risk group compared to the low-risk group (IRR 7.17, 95% CI: 3.05-16.82). The discriminatory ability was also similar in derivation (Harrell's C-statistic of 0.82 95% CI (0.76-0.88) and validation (0.82, 95% CI:0.72-0.92) cohorts. The risk score had a good discriminatory ability in both cohorts and helped to identify patients with higher risk of developing PTLD.
Mots-clé
EBV DNA, PTLD, SOT, transplantation
Pubmed
Web of science
Open Access
Oui
Création de la notice
19/07/2022 9:53
Dernière modification de la notice
23/01/2024 8:23
Données d'usage